Overview

Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432

Status:
Unknown status

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

Cohort study evaluate the efficacy treatment with OK-432 in cystic malformation of the head and neck region. The malformations are macrocystic and the preevaluation will include CT/MRI, US and blood tests. The injection will be in the OR under US guided, maximal dose will be 0.2mg. The follow-up will be of short term - till 30 days post injection and long term - follow-up wil be till 2 years.

Phase:

Phase 4

Details

Lead Sponsor:

Carmel Medical Center

Treatments:

Picibanil